Safety and Efficacy Study of the Effect of Etanercept in Hemodialysis Patients

Stopped early · Phase 2 · Has a placebo group

Conditions studied: End Stage Renal Disease

In brief

Etanercept is a novel anti-inflammatory agent currently used in patients with rheumatoid arthritis. We are examining whether Etanercept is effective in improving the nutritional status of hemodialysis patients as a consequence of its ability to decrease inflammation.

Key facts

Study ID

NCT00293202

Run by

Kaysen, George A., M.D., Ph.D.

People needed

10

Starts

2005-01-01

Expected to finish

2010-06-01

Last updated by the study team

2021-07-13

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Presence of end stage renal disease

You may not qualify if…

• History of Tuberculosis History of Recurrent Infection Recent AMI, Cancer within previous 5 years Presence of Hepatitis B, Hepatitis C, HIV, systemic lupus erythematosis, presence of transcutaneous access (external catheter)

Where it is running

• University of California, Davis, Medical Center — Sacramento, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.